Table 8.
Medicinal cannabis extract use preferences among various pain syndromes and “Yes” responses on ID Migraine™ questionnaire
| Cannabis extracts (drops, capsules) | ||||||
|---|---|---|---|---|---|---|
| Total | Hybrid | Indica | Sativa | 3:1 CBD:THC | 1:1 CBD:THC | |
| Headache as primary symptom (505) | 195 (38.6%) | 36 (18.5%) | 51 (26.2%) | 15 (7.7%) | 53 (27.2%) | 40 (20.5%) |
| Headache as primary illness (75) | 26 (34.7%) | 7 (26.9%) | 5 (19.2%) | 1 (3.9%) | 9 (34.6%) | 4 (15.4%) |
| Chronic pain as primary illness (598) | 248 (41.5%) | 44 (17.7%) | 56 (22.6%) | 18 (7.3%) | 60 (24.2%) | 66 (26.6%) |
| Arthritis as primary illness (188) | 80 (42.6%) | 14 (17.5%) | 11 (13.8%) | 5 (6.3%) | 26 (32.5%) | 24 (30%) |
| 3 Yes (343)a | 143 (41.7%) | 25 (17.5%) | 41 (28.7%) | 6 (4.2%) | 39 (27.3%) | 32 (22.4%) |
| 2 Yes (102)b | 33 (32.4%) | 6 (18.2%) | 7 (21.2%) | 5 (15.2%) | 9 (27.3%) | 6 (18.2%) |
| 3 + 2 Yes (445) | 176 (39.6%) | 31 (17.6%) | 48 (27.3%) | 11 (6.3%) | 48 (27.3%) | 38 (21.6%) |
a3 “Yes” responses = 97% probability of migraine
b2 “Yes” responses = 93% probability of migraine